HIV prevention vaginal ring found acceptable to adolescent girls
A vaginal ring containing the antiretroviral drug dapivirine had high adherence among young women, study finds
Source: International Partnership for Microbicides
Adolescent girls and young women account for 25% of new HIV infections in sub-Saharan Africa each year.
In research presented at the IAS Conference on HIV Science in Paris (25 July 2017), 96 sexually active girls aged 15–17 years in the USA were randomly assigned in a 3:1 ratio to use either a monthly placebo or a vaginal ring containing the antiviral dapivirine for six months. Adherence to ring use was assessed through self-report, plasma dapivirine concentrations and residual levels in used rings.
The researchers found that 42% of girls said they removed the ring only to change it once a month and blood serum levels indicated adherence of 87% to the dapivirine ring. The rate of adverse events was similar between the two groups.
The team says the results show that the ring is safe and acceptable for use by adolescent girls and plan to study its use in a larger population of adolescent girls in Africa.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203464
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now